耳鼻咽喉科・頭頸部外科91巻2号

2019年02月発行

特集 ここまできた！ 頭頸部希少癌の治療戦略

唾液腺導管癌

著者： 多田雄一郎¹

所属機関： ¹国際医療福祉大学三田病院頭頸部腫瘍センター

ページ範囲：P.136 - P.143

文献概要

POINT

●他の高悪性度唾液腺癌と同様に，初回治療の原則は，外科治療および高リスク症例の術後放射線治療である。

●切除不能再発転移例に対する治療として，NCCNガイドライン2018年版では，アンドロゲン受容体，HER2の発現を解析し，それぞれを治療標的とする薬物治療が提示された。

●日常臨床では，切除不能再発転移例に対する化学療法として，白金製剤とタキサン系抗癌剤の併用療法の報告が増えている。

●海外では遺伝子変異に応じて薬物を決定する治療報告が増えている。

参考文献

1）Tamaki T, et al：The burden of rare cancer in Japan：application of the RARECARE definition. Cancer Epidemiol 38：490-495, 2014

2）RARECARE Cancer List　http://www.rarecare.eu/rarecancers/rarecancers.asp

3）Boukheris H, et al：Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006：a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 18：2899-2906, 2009

4）Nagao T, et al：Salivary duct carcinoma. WHO classification of head and neck tumours, 4th ed. El-Naggar AK, et al（eds）. IARC, Lyon, 2017, pp159-202

5）Japan Society for Head and Neck Cancer, Cancer Registry Committee：Report of head and neck cancer registry of Japan, clinical statistics of registered patients, 2014. Major salivary glands（2014）. Jpn J Head Neck Cancer 42（Suppl）：103-115, 2016

6）Jaehne M, et al：Clinical and immunohistologic typing of salivary duct carcinoma：a report of 50 cases. Cancer 103：2526-2533, 2005

7）Gilbert MR, et al：A 20-year review of 75 cases of salivary duct carcinoma. JAMA Otolaryngol Head Neck Surg 142：489-495, 2016

8）Osborn V, et al：Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database. Oral Oncol 71：41-46, 2017

9）Jayaprakash V, et al：Survival rates and prognostic factors for infiltrating salivary duct carcinoma：Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck 36：694-701, 2014

10）Otsuka K, et al：Clinical outcomes and prognostic factors for salivary duct carcinoma：a multi-institutional analysis of 141 patients. Ann Surg Oncol 23：2038-2045, 2016

11）Kawakita D, et al：Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma：a multi-institutional study in Japan. Oncotarget 8： 1083-1091, 2016

12）Nagao T, et al：Sarcomatoid variant of salivary duct carcinoma：clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Clin Pathol 122：222-231, 2004

13）Nagao T, et al：Invasive micropapillary salivary duct carcinoma：a distinct histologic variant with biologic significance. Am J Surg Pathol 28：319-326, 2004

14）Takase S, et al：Biomarker immunoprofile in salivary duct carcinomas：clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget 8：59023-59035, 2017

15）Urano M, et al：The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas：a study of 142 cases. Histopathology, 2018　doi：10.1111/his.13706［Epub ahead of print］

16）Boon E, et al：A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int J Cancer 143：758-766, 2018

17）Shimura T, et al：Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. Oncotarget 9：1852-1867, 2017

18）Lewis AG, et al：Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin North Am 49：343-380, 2016

19）NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers　https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf（accessed 2018/9/28）

20）Sood S, et al：Management of salivary gland tumours：United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 130：S142-S149, 2016

21）日本頭頸部癌学会（編）：頭頸部癌診療ガイドライン2018年版．金原出版，東京，2018，pp70-73［唾液腺癌（耳下腺癌）］

22）Guntinas-Lichius O et al：Management of the facial nerve in parotid cancer：preservation or resection and reconstruction. Eur Arch Otorhinolaryngol 275：2615-2626, 2018

23）Mahmood U, et al：Adjuvant radiation therapy for high-grade and/or locally advanced major salivary gland tumors. Arch Otolaryngol Head Neck Surg 137：1025-1030, 2011

24）Hayashi K, et al：A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas：Subanalysis of J-CROS 1402 HN. Cancer Sci 109：1576-1582, 2018

25）日本臨床腫瘍学会（編）：頭頸部がん薬物療法ガイダンス 第2版．金原出版，東京，2018

26）Alfieri S et al：Systemic therapy in metastatic salivary gland carcinomas：a pathology-driven paradigm? Oral Oncol 66：58-63, 2017

27）Nakano K, et al：Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients：differences in responses by different pathological diagnoses. Acta Otolaryngol 136：948-951, 2016

28）Licitra L, et al：Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase Ⅱ trial of 22 patients. Ann Oncol 7：640-642, 1996

29）Laurie SA et al：A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer：a trial of the NCIC Clinical Trials Group. Cancer 116：362-368, 2010

30）Airoldi M, et al：Cisplatin＋vinorelbine treatment of recurrent or metastatic salivary gland malignancies（RMSGM）：a final report on 60 cases. Am J Clin Oncol 40：86-90, 2017

31）Weigelt B, et al：Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 9：58-64, 2011

32）Fushimi C, et al：A prospective phase Ⅱ study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29：979-984, 2018

33）Takahashi H, et al：Phase Ⅱ trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol, 2018　doi：10.1200/JCO.18.00545［Epub ahead of print］

34）黒田裕行・他：抗アンドロゲン療法と化学療法が奏効した進行唾液腺導管癌の1例．癌と化療38：627-630，2011

35）Yajima Y, et al：Anti-androgen therapy for the patients with recurrent and/or metastatic salivary duct carcinoma expressing androgen receptors：a retrospective study. Ann Oncol 23：Abs 1706, 2012

36）Yamamoto N, et al：Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy. Am J Otolaryngol 35：731-735, 2014

37）菅野真史・他：アンドロゲンレセプター陽性進行唾液腺導管癌に対する抗アンドロゲン療法の臨床検討．頭頸部癌43：49-55，2017

38）大江祐一郎・他：唾液腺導管癌局所再発・多発骨転移に対しビカルタミドが奏功した1例．頭頸部癌43：478-482，2017

39）Wasano K, et al：Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma：a case report. Rare Tumors 10：2036361318798867, 2018

40）Kawakita D, et al：Novel approach for unresectable salivary duct carcinoma：Targeting HER2 and androgen receptor. J Clin Oncol 36（suppl）：abstr 6084, 2018

41）Cohen RB, et al：Pembrolizumab for the treatment of advanced salivary gland carcinoma：findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol 41：1083-1088, 2018

V600 mutations. N Engl J Med 373：726-736, 2015

fusion-positive cancers in adults and children. N Engl J Med 378：731-739, 2018

44）Hainsworth JD, et al：Targeted therapy for advanced solid tumors on the basis of molecular profiles：results from MyPathway, an Open-Label, Phase Ⅱa Multiple Basket Study. J Clin Oncol 36：536-542, 2018

45）van Boxtel W, et al：Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. Oral Oncol 72：198-200, 2017

46）Li BT, et al：A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol 36（suppl）：abstr 2502, 2018

47）Jhaveri KL, et al：Ado-trastuzumab emtansine（T-DM1）in patients（pts）with HER2 amplified（amp）tumors excluding breast and gastric/gastro-esophageal junction（GEJ）adenocarcinomas：results from the National Cancer Institute（NCI）Molecular Analysis for Therapy Choice（MATCH）trial. J Clin Oncol 36（suppl）：abstr 100, 2018

48）Iwata H, et al：Trastuzumab deruxtecan（DS-8201a）in subjects with HER2-expressing solid tumors：Long-term results of a large phase 1 study with multiple expansion cohorts. J Clin Oncol 36（suppl）：abstr 2501, 2018

-mutated salivary duct carcinoma with combined BRAF and MEK inhibition. J Natl Compr Canc Netw 16：1166-1170, 2018

50）Wang K, et al：Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res 22：6061-6068, 2016

51）Locati LD, et al：Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biol Ther 15：678-682, 2014

52）Urban D, et al：Abiraterone in metastatic salivary duct carcinoma. J Natl Compr Canc Netw 13：288-290, 2015